Calton & Associates »

Crispr Therapeutics shares owned by Calton & Associates

Quarter-by-quarter ownership of Crispr Therapeutics (CRSP) shares owned by Calton & Associates from 13F filings

Historical chart of Calton & Associates investment in Crispr Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Crispr Therapeutics held by Calton & Associates consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crispr Therapeutics by Calton & Associates

Quarter filed Position value Share count Share price at filing
2025-12-31 $221k 4.2k 52.44

More positions owned by Calton & Associates

Invesco Qqq Tr Unit Ser 1 (QQQ)
Northern Lts Fd Tr Ii Peakshares Secto (PSTR)
Spdr Series Trust State Street Spd (SPYM)
Apple (AAPL)
Fidelity Covington Trust High Divid Etf (FDVV)
Wisdomtree Tr Floatng Rat Trea (USFR)
Schwab Strategic Tr Us Lcap Gr Etf (SCHG)
Spdr Series Trust State Street Spd (BIL)
Invesco Actively Managed Exc Var Rate Invt (VRIG)
Vanguard World Financials Etf (VFH)
Vanguard Index Fds Growth Etf (VUG)
Select Sector Spdr Tr State Street Tec (XLK)
Dbx Etf Tr Xtrack Msci Eafe (DBEF)
Spdr Series Trust State Street Spd (FLRN)
Vanguard World Mega Cap Index (MGC)

View all positions for Calton & Associates

Top funds holding Crispr Therapeutics

ARK Investment Management
BlackRock
Orbis Allan Gray
Capital Research and Management Company - Division 3
State Street Corporation
T. Rowe Price Investment Management
UBS Group
Vanguard Group
Geode Capital Management
Susquehanna International
Sr One Capital Management
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
Citadel Advisors
FMR

View all funds holding Crispr Therapeutics